# Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia

> **NCT00726232** · PHASE2 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 73 (actual)

## Conditions studied

- Myeloproliferative Neoplasm (MPN)

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT00726232
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-08-20
- **Primary completion:** 2010-06-20
- **Final completion:** 2018-08-20
- **Target enrollment:** 73 (ACTUAL)
- **Why stopped:** Termination of the clinical trial by sponsor.
- **Last updated:** 2025-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00726232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00726232, "Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00726232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*